PL
TGTX icon

Parkwood LLC’s TG Therapeutics TGTX Stock Holding History

Parkwood LLC’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-147,680
Closed -$9.85M – 129
2024
Q2 		$9.85M Buy
147,680
+131,609
+819% +$2.1M 1.22% 31
2024
Q1 		$8.63M Sell
16,071
-8,276
-34% -$132K 0.78% 44
2023
Q4 		$1.88M Sell
24,347
-141,067
-85% -$1.64M 0.23% 73
2023
Q3 		$6.08M Buy
+165,414
New +$2.31M 0.66% 36
2023
Q2 		– Sell
-21,415
Closed -$531K – 166
2023
Q1 		$531K Sell
21,415
-5,441
-20% -$82.6K 0.07% 112
2022
Q4 		$5.5M Sell
26,856
-1,442,427
-98% -$10.5M 0.83% 33
2022
Q3 		$10.7M Buy
1,469,283
+1,422,115
+3,015% +$9.33M 1.62% 8
2022
Q2 		$1.38M Sell
47,168
-2,758
-6% -$17.2K 0.25% 84
2022
Q1 		$4.69M Buy
49,926
+46,406
+1,318% +$537K 0.77% 49
2021
Q4 		$4.85M Sell
3,520
-36,801
-91% -$955K 0.83% 51
2021
Q3 		$5.15M Buy
40,321
+13,398
+50% +$415K 0.62% 45
2021
Q2 		$1.89M Sell
26,923
-5,052
-16% -$198K 0.22% 79
2021
Q1 		$1.54M Buy
31,975
+502
+2% +$24.1K 0.27% 68
2020
Q4 		$1.64M Buy
+31,473
New +$1.06M 0.2% 79

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Parkwood LLC's TGTX Position: Q3 2024 in Review

Parkwood LLC sold out of TG Therapeutics (TGTX) in Q3 2024, closing a stake of 147,680 shares — an estimated $9.85M sold.

Parkwood LLC first reported a position in TGTX in Q4 2020 and held it in 14 quarters. The position peaked at $10.7M in Q3 2022. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • Parkwood LLC reported no remaining TG Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Parkwood LLC sold 147,680 TG Therapeutics shares in Q3 2024, an estimated $9.85M.
  • Parkwood LLC first reported a position in TG Therapeutics in Q4 2020 and held it in 14 quarters.
  • Parkwood LLC's TG Therapeutics position peaked at $10.7M in Q3 2022.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on Parkwood LLC's 13F filing for Q3 2024, filed 14 Nov 2024.